Comparable efficacy and safety between LY2963016 insulin glargine and insulin glargine (Lantus®) in Chinese patients with type 1 diabetes: A phase III , randomized, controlled trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Comparable efficacy and safety between LY2963016 insulin glargine and insulin glargine (Lantus®) in Chinese patients with type 1 diabetes: A phase III , randomized, controlled trial

Published:2021-07-08 Issue:10 Volume:23 Page:2226-2233
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Yan Xiang¹,Jiang Shan²,Lou Ying³,Zhou Zhiguang¹^ORCID

Affiliation:

1. National Clinical Research Center for Metabolic Diseases, Key Laboratory of Diabetes Immunology (Central South University), Ministry of Education, and Department of Metabolism and Endocrinology The Second Xiangya Hospital of Central South University Changsha China

2. Lilly (Shanghai) Management Co., Ltd Shanghai China

3. Lilly Suzhou Pharmaceutical Co., Ltd Shanghai China

Funder

Eli Lilly and Company

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.14463

Reference33 articles.

1. Diabetes Mellitus Review

2. Epidemiological Perspectives of Diabetes

3. International Diabetes Federation. IDF Diabetes Atlas 9th edn Brussels Belgium: 2019.https://www.diabetesatlas.org/en/.

4. The beneficial effect of insulin degludec on nocturnal hypoglycaemia and insulin dose in type 1 diabetic patients: a systematic review and meta-analysis of randomised trials

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New Insulins, Biosimilars, and Insulin Therapy;Diabetes Technology & Therapeutics;2023-02-01

2. Efficacy and Safety of LY2963016 Insulin Glargine in Chinese Patients with Type 1 Diabetes Previously Treated with Insulin Glargine (Lantus®): a Post Hoc Analysis of a Randomized, Open-Label, Phase 3 Trial;Diabetes Therapy;2022-04-26

3. New Insulins, Biosimilars, and Insulin Therapy;Diabetes Technology & Therapeutics;2022-04-01

4. Immunogenicity of LY2963016 insulin glargine and Lantus® insulin glargine in Chinese patients with type 1 or type 2 diabetes mellitus;Diabetes, Obesity and Metabolism;2022-03-20

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3